About Acomplia

Acomplia (Rimonabant), the eagerly awaited weight loss drug works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System). The EC System is believed to play a critical role in the regulation of food intake and energy expenditure of our body.

Research findings indicate that these receptors are present on the surfaces of many cells throughout the body including fat cells and those in the hypothalamus - the brain region that is thought to determine our appetite. The chemical compounds produced by our body known as cannabinoids, latch on to the CB1 receptors, which are overactive in overweight and obese individuals, sending out a signal that prompts people to eat more and in the process makes them put on weight.

But with the usage of diet pill Acomplia, we can halt the action of cannabinoid receptors and in the process will be capable of curbing our appetite. Studies conducted in the past have proved that genetically altered mice that lacked cannabinoid receptors ate less than their little mates even after 18 hours of fasting. It has also been observed that the administration of rimonabant in normal mice has helped in reducing their food intake.

Acomplia (Rimonabant) is a class apart from other available diet pills as it works by selectively targeting and blocking the CB1 receptors. This procedure helps in normalizing the over-activation of the EC system and makes hunger or cigarette pangs more manageable for its users.

The blocking of CB1 receptors by Acomplia that helps in controlling food cravings gradually results in weight loss, improvement of cardiovascular/ metabolic risk factors in overweight/obese patients and appears to reduce tobacco dependence without post cessation weight gain in people who smoke.

So, apart from its weight loss benefits, Acomplia can provide great relief to smokers by helping them overcome the life threatening habit.